Artificial intelligence in drug repurposing for rare diseases: a mini-review

Front Med (Lausanne). 2024 May 22:11:1404338. doi: 10.3389/fmed.2024.1404338. eCollection 2024.

Abstract

Drug repurposing, the process of identifying new uses for existing drugs beyond their original indications, offers significant advantages in terms of reduced development time and costs, particularly in addressing unmet medical needs in rare diseases. Artificial intelligence (AI) has emerged as a transformative force in healthcare, and by leveraging AI technologies, researchers aim to overcome some of the challenges associated with rare diseases. This review presents concrete case studies, as well as pre-existing platforms, initiatives, and companies that demonstrate the application of AI for drug repurposing in rare diseases. Despite representing a modest part of the literature compared to other diseases such as COVID-19 or cancer, the growing interest, and investment in AI for drug repurposing in rare diseases underscore its potential to accelerate treatment availability for patients with unmet medical needs.

Keywords: artificial intelligence; deep learning; drug repurposing; machine learning; rare diseases.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This material is based on the study supported by the Association nationale de la recherche et de la technologie (ANRT) with a CIFRE fellowship granted to LC.